Article
Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial.
British journal of cancer - 1 Jun 2026
Huismans Maarten A, Gort Eelke H, van der Heijden Lisa T, Guven Mese Sermin M, Klein Wolterink Helena M, Braat Manon N G J A, Elias Sjoerd G, de Vos Filip Y F L, Devriese Lot A, Verheul Henk M W, Opdam Frans L, Koopman Miriam, Nienhuis Hilde H, Crommelin Heleen A, Snippert Hugo J G, Huitema Alwin D R, Roodhart Jeanine M L
Abstract excerpt
BACKGROUND: Treatment options for RAS-mutant metastatic colorectal cancer (mCRC) remain limited. Based on preclinical work with patient-derived organoids, we investigated a triple therapy of binimetinib, lapatinib, and vinorelbine in a Phase I/II trial. METHODS: Forty patients with RAS-mutant mCRC received escalating doses of binimetinib and lapatinib with vinorelbine 17.5 mg/m² in three-weekly schedules. Phase I...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.